TY - JOUR
T1 - Molecular epidemiology and antimicrobial susceptibility of Clostridium difficile isolates from a university teaching hospital in China
AU - Cheng, Jing Wei
AU - Xiao, Meng
AU - Kudinha, Timothy
AU - Kong, Fanrong
AU - Xu, Zhi Peng
AU - Sun, Lin Ying
AU - Zhang, Li
AU - Fan, Xin
AU - Xie, Xiu Li
AU - Xu, Ying Chun
N1 - Includes bibliographical references.
PY - 2016/10/17
Y1 - 2016/10/17
N2 - While the developed world has seen a significant increase in the number of scientific articles on Clostridium difficile infection (CDI), the developing world still lags behind on this subject due to limited laboratory capacity, low awareness, and limited surveillance of this problem. As such, CDI is considered a neglected but potentially huge problem in developing countries. The major aim of this study was to systemically evaluate the utility of several molecular typing tools for CDI, including their relevance in epidemiological studies in developing countries such as China. A total of 116 non-repetitive toxigenic C. difficile isolates from Chinese patients, were studied. The isolates comprised 83 (71.6%) A+B+CDT- isolates, 27 (23.3%) A-B+CDT- isolates, and 6 (5.1%) A+B+CDT+ isolates. Typing methods evaluated included multilocus variable-number tandem-repeat analysis, PCR ribotyping, multilocus sequence typing, and sequencing of slpA and tcdC genes, which identified 113, 30, 22, 18, and 8 genotypes each and exhibited discriminatory powers of 0.999, 0.916, 0.907, 0.883, and 0.765, respectively. Compared to A+B+ strains, A-B+ strains exhibited higher prevalence of drug resistance to clindamycin, erythromycin, levofloxacin, rifampicin, rifaximin, and tetracycline. Furthermore, drug resistance rates of strains with different PCR ribotypes differed, supporting the importance of molecular typing in management and control of CDI. Based on our earlier suggestion to improve the diagnostic laboratory capacity of CDI in developing countries, setting up efficient surveillance programs complemented by relevant molecular typing methods is warranted.
AB - While the developed world has seen a significant increase in the number of scientific articles on Clostridium difficile infection (CDI), the developing world still lags behind on this subject due to limited laboratory capacity, low awareness, and limited surveillance of this problem. As such, CDI is considered a neglected but potentially huge problem in developing countries. The major aim of this study was to systemically evaluate the utility of several molecular typing tools for CDI, including their relevance in epidemiological studies in developing countries such as China. A total of 116 non-repetitive toxigenic C. difficile isolates from Chinese patients, were studied. The isolates comprised 83 (71.6%) A+B+CDT- isolates, 27 (23.3%) A-B+CDT- isolates, and 6 (5.1%) A+B+CDT+ isolates. Typing methods evaluated included multilocus variable-number tandem-repeat analysis, PCR ribotyping, multilocus sequence typing, and sequencing of slpA and tcdC genes, which identified 113, 30, 22, 18, and 8 genotypes each and exhibited discriminatory powers of 0.999, 0.916, 0.907, 0.883, and 0.765, respectively. Compared to A+B+ strains, A-B+ strains exhibited higher prevalence of drug resistance to clindamycin, erythromycin, levofloxacin, rifampicin, rifaximin, and tetracycline. Furthermore, drug resistance rates of strains with different PCR ribotypes differed, supporting the importance of molecular typing in management and control of CDI. Based on our earlier suggestion to improve the diagnostic laboratory capacity of CDI in developing countries, setting up efficient surveillance programs complemented by relevant molecular typing methods is warranted.
KW - Antimicrobial resistance
KW - China
KW - Clostridium difficile
KW - Molecular typing
KW - Surveillance
UR - http://www.scopus.com/inward/record.url?scp=84996644282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84996644282&partnerID=8YFLogxK
U2 - 10.3389/fmicb.2016.01621
DO - 10.3389/fmicb.2016.01621
M3 - Article
C2 - 27799923
AN - SCOPUS:84996644282
SN - 1664-302X
VL - 7
SP - 1
EP - 10
JO - Frontiers in Microbiology
JF - Frontiers in Microbiology
IS - OCT
M1 - 1621
ER -